Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention

Simply Wall St.04-23 22:11

Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629732853?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-23 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629732853","market":"hk","top_or_hot":-1,"title":"Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention","media":"Simply Wall St.","content":"<div>\n<p>Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-gains-china-felzartamab-rights-as-valuation-gap-draws\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Gains China Felzartamab Rights As Valuation Gap Draws Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 22:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-gains-china-felzartamab-rights-as-valuation-gap-draws><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-gains-china-felzartamab-rights-as-valuation-gap-draws\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-gains-china-felzartamab-rights-as-valuation-gap-draws","article_id":"2629732853","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-gains-china-felzartamab-rights-as-valuation-gap-draws","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629732853","pubTimestamp":1776953512,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma.\nThe deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for multiple immune mediated diseases.\nBiogen will lead development and commercialization of felzartamab in Greater China, a key market for conditions such as IgAN and PMN.\n\nFor investors tracking Biogen, this move adds a late stage immunology asset to a pipeline already focused on serious...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BIIB":"渤健公司","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4139":"生物科技"},"translate_title":"估值差距引关注Biogen获得中国Felzartamab权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felzartamab, an antibody in Phase 3 trials for multiple immune mediated diseases. Biogen will lead development and commercialization of felzartamab in Greater China, a key market for conditions such as IgAN and PMN.  For investors tracking Biogen, this move adds a late stage immunology asset to a pipeline already focused on serious neurological and immune mediated conditions. Felzartamab targets diseases with large patient populations in China, including IgA nephropathy and primary membranous nephropathy, where treatment options can be limited. Control of Greater China rights means Biogen can align clinical development and commercial plans for felzartamab across regions. This can matter for trial design, regulatory timing, and eventual launch strategies. Readers watching NasdaqGS:BIIB may view this as part of a broader effort to build scale in immunology and increase exposure to one of the world’s largest pharmaceutical markets. Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen. NasdaqGS:BIIB Earnings & Revenue Growth as at Apr 2026 We've flagged 1 risk for Biogen. See which could impact your investment. AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: At US$190.07, Biogen trades around 10.2% below the US$211.69 analyst target, suggesting a modest discount to consensus. ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading about 51.2% below its fair value, pointing to a meaningful valuation gap. ✅ Recent Momentum: The stock has returned roughly 3.5% over the last 30 days, showing recent positive momentum.  There is only one way to know the right time to buy, sell or hold Biogen: review the latest detailed analysis. Head to Simply Wall St's\ncompany report for the latest analysis of Biogen's Fair Value. Key Considerations  📊 Consolidating global rights to felzartamab gives Biogen clearer control over a late stage immunology asset that could complement its existing focus on serious immune mediated conditions. 📊 Investors may wish to monitor progress of Phase 3 trials, any regulatory updates in Greater China, and how the US$190.07 share price compares with the US$211.69 analyst target and 21.6x P/E. ⚠️ Simply Wall St flags one minor risk related to large one off items affecting financial results, so investors may want to separate recurring earnings from exceptional items when assessing valuation.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Biogen analysis. Alternatively, you can visit the\ncommunity page for Biogen to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629732853","isCrawlerRequest":true}